{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?page=57&sponsor=AstraZeneca",
    "query": {
      "sponsor": "AstraZeneca",
      "page": 57
    },
    "page_size": 10
  },
  "pagination": {
    "page": 57,
    "page_size": 10,
    "total_count": 1904,
    "total_pages": 191,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=58&sponsor=AstraZeneca&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?page=56&sponsor=AstraZeneca&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-04T10:48:23.816Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04609878",
      "title": "Study to Assess PT010 in Adult and Adolescent Participants With Inadequately Controlled Asthma (KALOS)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "BGF MDI 320/28.8/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "BGF MDI 320/14.4/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "BFF MDI 320/9.6 μg",
          "type": "DRUG"
        },
        {
          "name": "BFF pMDI 320/9 μg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "12 Years to 80 Years"
      },
      "enrollment_count": 2274,
      "start_date": "2020-12-15",
      "completion_date": "2025-03-21",
      "has_results": true,
      "last_update_posted_date": "2026-06-30",
      "last_synced_at": "2026-11-04T10:48:23.816Z",
      "location_count": 107,
      "location_summary": "Saraland, Alabama • Phoenix, Arizona • Sun City West, Arizona + 96 more",
      "locations": [
        {
          "city": "Saraland",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City West",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04609878"
    },
    {
      "nct_id": "NCT06269484",
      "title": "A Phase IIb Study to Evaluate the Safety of Zibotentan/Dapagliflozin in Participants With Cirrhosis-ZEAL-UNLOCK",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Liver Cirrhosis"
      ],
      "interventions": [
        {
          "name": "Placebo (placebo matching zibotentan capsule and placebo matching dapagliflozin tablet)",
          "type": "DRUG"
        },
        {
          "name": "Zibotentan + placebo (placebo matching dapagliflozin tablet)",
          "type": "DRUG"
        },
        {
          "name": "Zibotentan + dapagliflozin",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 73,
      "start_date": "2024-02-15",
      "completion_date": "2024-12-11",
      "has_results": true,
      "last_update_posted_date": "2026-01-20",
      "last_synced_at": "2026-11-04T10:48:23.816Z",
      "location_count": 3,
      "location_summary": "Englewood, Colorado • Charleston, South Carolina • San Antonio, Texas",
      "locations": [
        {
          "city": "Englewood",
          "state": "Colorado"
        },
        {
          "city": "Charleston",
          "state": "South Carolina"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06269484"
    },
    {
      "nct_id": "NCT05351047",
      "title": "A Study to Assess Safety, Tolerability, PK and PD of AZD2373 in Healthy Male Participants of Sub-Saharan West African Ancestry",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "AZD2373 subcutaneous injection",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "MALE",
        "summary": "18 Years to 55 Years · Male only"
      },
      "enrollment_count": 24,
      "start_date": "2022-04-04",
      "completion_date": "2023-07-06",
      "has_results": false,
      "last_update_posted_date": "2023-08-07",
      "last_synced_at": "2026-11-04T10:48:23.816Z",
      "location_count": 1,
      "location_summary": "Brooklyn, Maryland",
      "locations": [
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05351047"
    },
    {
      "nct_id": "NCT06595238",
      "title": "A Study in Participants With Obesity or Overweight With at Least One Weight-related Comorbidity",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Obesity or Overweight"
      ],
      "interventions": [
        {
          "name": "AZD6234",
          "type": "DRUG"
        },
        {
          "name": "Placebo comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 262,
      "start_date": "2024-10-01",
      "completion_date": "2025-12-03",
      "has_results": false,
      "last_update_posted_date": "2026-10-02",
      "last_synced_at": "2026-11-04T10:48:23.816Z",
      "location_count": 23,
      "location_summary": "Mobile, Alabama • Phoenix, Arizona • Long Beach, California + 19 more",
      "locations": [
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Long Beach",
          "state": "California"
        },
        {
          "city": "Hialeah",
          "state": "Florida"
        },
        {
          "city": "Largo",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06595238"
    },
    {
      "nct_id": "NCT07316608",
      "title": "A Phase I Study Comparing the Relative Bioavailability of a Fixed-Dose Combination of Laroprovstat/Rosuvastatin vs Their Single Therapy Products in Healthy Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Participants"
      ],
      "interventions": [
        {
          "name": "Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 1",
          "type": "DRUG"
        },
        {
          "name": "Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 1",
          "type": "DRUG"
        },
        {
          "name": "Laroprovstat Dose X/Rosuvastatin Dose 1 FCDP test formulation 2",
          "type": "DRUG"
        },
        {
          "name": "Laroprovstat Dose X/Rosuvastatin Dose 2 FCDP test formulation 2",
          "type": "DRUG"
        },
        {
          "name": "Laroprovstat Dose X STP",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin Dose 1 STP",
          "type": "DRUG"
        },
        {
          "name": "Rosuvastatin Dose 2 STP",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 44,
      "start_date": "2026-03-16",
      "completion_date": "2026-06-05",
      "has_results": false,
      "last_update_posted_date": "2026-06-17",
      "last_synced_at": "2026-11-04T10:48:23.816Z",
      "location_count": 2,
      "location_summary": "Glendale, California • Brooklyn, Maryland",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Brooklyn",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07316608"
    },
    {
      "nct_id": "NCT06238466",
      "title": "A Study to Investigate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AZD1705 in Participants With Dyslipidemia",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Cardiovascular"
      ],
      "interventions": [
        {
          "name": "AZD1705",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 98,
      "start_date": "2024-01-16",
      "completion_date": "2027-04-08",
      "has_results": false,
      "last_update_posted_date": "2026-08-05",
      "last_synced_at": "2026-11-04T10:48:23.816Z",
      "location_count": 5,
      "location_summary": "Glendale, California • Jacksonville, Florida • Winter Park, Florida + 2 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Winter Park",
          "state": "Florida"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06238466"
    },
    {
      "nct_id": "NCT03693300",
      "title": "A Study to Determine Safety of Durvalumab After Sequential Chemo Radiation in Patients With Unresectable Stage III Non-Small Cell Lung Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Non-small Cell Lung Cancer (NSCLC)"
      ],
      "interventions": [
        {
          "name": "Durvalumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "130 Years",
        "sex": "ALL",
        "summary": "18 Years to 130 Years"
      },
      "enrollment_count": 117,
      "start_date": "2019-04-16",
      "completion_date": "2023-04-21",
      "has_results": true,
      "last_update_posted_date": "2024-06-18",
      "last_synced_at": "2026-11-04T10:48:23.816Z",
      "location_count": 2,
      "location_summary": "Gainesville, Georgia • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Georgia"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03693300"
    },
    {
      "nct_id": "NCT00280865",
      "title": "GLAD: Dose-Finding, Efficacy, and Safety of AZ 242 (Tesaglitazar) in Subjects With Type 2 Diabetes",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Type 2 Diabetes"
      ],
      "interventions": [
        {
          "name": "Tesaglitazar",
          "type": "DRUG"
        },
        {
          "name": "Pioglitazone",
          "type": "DRUG"
        },
        {
          "name": "Dietary and Lifestyle Modification Counseling",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BEHAVIORAL"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "30 Years to 50 Years"
      },
      "enrollment_count": 500,
      "start_date": "2002-04",
      "completion_date": "2003-06",
      "has_results": false,
      "last_update_posted_date": "2006-07-31",
      "last_synced_at": "2026-11-04T10:48:23.816Z",
      "location_count": 90,
      "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Montgomery, Alabama + 87 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Huntsville",
          "state": "Alabama"
        },
        {
          "city": "Montgomery",
          "state": "Alabama"
        },
        {
          "city": "Mesa",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00280865"
    },
    {
      "nct_id": "NCT02245737",
      "title": "An Efficacy and Safety Study of Lanabecestat (LY3314814) in Early Alzheimer's Disease",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Alzheimer´s Disease"
      ],
      "interventions": [
        {
          "name": "Lanabecestat",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AstraZeneca",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "55 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "55 Years to 85 Years"
      },
      "enrollment_count": 2218,
      "start_date": "2014-09-30",
      "completion_date": "2018-10-04",
      "has_results": true,
      "last_update_posted_date": "2019-12-03",
      "last_synced_at": "2026-11-04T10:48:23.816Z",
      "location_count": 77,
      "location_summary": "Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 58 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Sun City",
          "state": "Arizona"
        },
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Fremont",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02245737"
    },
    {
      "nct_id": "NCT02911792",
      "title": "Effect of Farxiga on Renal Function and Size in Type 2 Diabetic Patients With Hyperfiltration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Diabetes Mellitus, Type 2"
      ],
      "interventions": [
        {
          "name": "Dapagliflozin",
          "type": "DRUG"
        },
        {
          "name": "Metformin",
          "type": "DRUG"
        },
        {
          "name": "Glipizide 5 MG",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "The University of Texas Health Science Center at San Antonio",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "30 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "30 Years to 70 Years"
      },
      "enrollment_count": 72,
      "start_date": "2016-12-20",
      "completion_date": "2023-07-11",
      "has_results": true,
      "last_update_posted_date": "2023-11-30",
      "last_synced_at": "2026-11-04T10:48:23.816Z",
      "location_count": 2,
      "location_summary": "San Antonio, Texas",
      "locations": [
        {
          "city": "San Antonio",
          "state": "Texas"
        },
        {
          "city": "San Antonio",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02911792"
    }
  ]
}